Entrar/Registro  
HOME SPANISH
 
Veterinaria México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Veterinaria México >Year 2008, Issue 2


Bautista GCR, Torres ÁMC
The inoculation of Lactobacillus casei in NIH mice induces a protective response against Trypanosoma cruzi (Ninoa strain) infection
Vet Mex 2008; 39 (2)

Language: English/Spanish
References: 20
Page: 139-144
PDF: 169.58 Kb.


Full text




ABSTRACT

The aim of the present study was to evaluate the effect of Lactobacillus casei administered orally or intraperitoneally to NIH mice, on the experimental infection with Trypanosoma cruzi Ninoa strain. Twenty three NIH mice were randomly distributed into three groups, which were treated seven days before the infection with 12 × 104 Trypanosoma cruzi, Ninoa strain. The animals in the control group (n = 7) received sterile saline solution by intraperitoneal (ip) route; those in the Lc-O group (n = 8) were treated with Lactobacillus casei by oral route, and those in the Lc-IP group (n = 8) received L. casei by ip. The mice treated with the lactobacilli showed a reduced number of blood parasites after challenge, as compared with those of the control group (P ‹ 0.01). Similarly, the mice treated with L. casei by ip route showed a signifi cant minor total number of parasites after challenge, than those of the group treated with L. casei by oral route (P ‹0.05). The results suggest that the treatment of mice with L. casei, both orally and intraperitoneally, induces a protective response against the experimental infection with Trypanosoma cruzi Ninoa strain.


Key words: TRYPANOSOMA CRUZI, LACTOBACILLUS CASEI, ADJUVANT, RESISTANCE.


REFERENCIAS

  1. 1.Morel CM, Lazdins J. Chagas disease. Nat Rev Microbiol 2003;1:14-15.

  2. 2.Guzmán-Bracho C. Enfermedad de Chagas en Progreso,Jiutepec, Mor. I. Encuesta seroepidemiológica (tesis de especialidad). México DF: Instituto de Salubridad y Enfermedades Tropicales, Secretaría de Salud,1985.

  3. 3.Rozas M, Botto-Mahan C, Coronado X, Ortiz S, Cattan PE, Solari A. Short report: Trypanosoma cruzi infection in wild mammals from a chagasic area of Chile. Am J Trop Med Hyg 2005;73:517-519.

  4. 4.Salazar-Schettino PM, Bucio MI, Cabrera M, Bautista J. First case of natural infection in pigs. Review of Trypanosoma cruzi reservoirs in Mexico. Mem Inst Oswaldo Cruz 1997;92:499-502.

  5. 5.Beard CB, Pye G, Steurer FJ, Rodriguez R, Campman R, Peterson AT et al. Chagas disease in a domestic transmission cycle in southern Texas, USA. Emerg Infect Dis 2003;9:103-105.

  6. 6.World Health Organization. Control of Chagas disease:second report of the WHO expert committee. UNDP/ WHO. Geneva: The Organization, 2002.

  7. 7.Guzman-Bracho C. Epidemiology of Chagas disease in Mexico: an update. Trends Parasitol 2001;17:372-376.

  8. 8.Lopez-Cardenas J, Gonzalez FE, Salazar PM, Gallaga JC, Ramirez E, Martinez J et al. Fine-scale predictions of distributions of Chagas disease vectors in the state of Guanajuato, Mexico. J Med Entomol 2005;42:1068- 1081.

  9. 9.Cruz-Reyes A, Pickering-Lopez JA. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years – A review. Mem Inst Oswaldo Cruz, Rio de Janeiro 2006;101:345-354.

  10. 10.Anonimo. Department of Health and Human Services.Chagas disease. Centers for Disease Control and Prevention. Division of Parasitic Diseases. Facts sheet. 2004:1-3.

  11. 11.Bautista-Garfi as CR, Ixta-Rodriguez O, Martinez-Gomez F, Lopez MG, Aguilar-Figueroa BR. Effect of viable or dead Lactobacillus casei organisms adminis-tered orally to mice on resistance against Trichinella spiralis infection. Parasite 2001; 8: S226-228.

  12. 12.Bautista-Garfi as CR, Gomez MB, Aguilar BR, Ixta O,Martinez F, Mosqueda J. The treatment of mice with Lactobacillus casei induces protection against Babesia microti infection. Parasitol Res 2005;97:472-477.

  13. 13.Bautista-Garfi as CR, Arriola MT, Trejo L, Ixta O, Rojas EE. Comparative effect between Lactobacillus casei and a commercial vaccine against coccidiosis in broilers. Téc Pecu Méx 2003;41:317-327.

  14. 14.Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.Rev Inst Med Trop Sao Paulo 1962;4:389-396.

  15. 15.Olivares Sáenz E. Paquete de diseños experimentales.Marín (NL) México: Facultad de Agronomía. Universidad Autónoma de Nuevo León, 1994.

  16. 16.Oliveira AC, Peixoto JR, de Arruda LB, Campos MA,Gazzinelli RT, Golenbock DT et al. Expression of functional TLR4 confers proinfl ammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol 2004;173:5688-5696.

  17. 17.Bautista Garfi as CR, Mosqueda JJ. Papel de los receptores tipo Toll y su implicación en Medicina Veterinaria.Vet Méx 2005;36:453-468.

  18. 18.Maldonado Galdeano C, Perdigón G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity.Clin Vaccine Immunol 2006;13:219-226.

  19. 19.Cardillo F, Voltarelli JC, Reed SG, Silva JS. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun 1996;64:128-134.

  20. 20.Bautista-Garfi as CR, Ixta O, Orduña M, Martinez F,Aguilar B, Cortes A. Enhancement of resistance in mice treated with Lactobacillus casei: effect on Trichinella spiralis infection. Vet Parasitol 1999;80:251-260.






>Journals >Veterinaria México >Year 2008, Issue 2
 

· Journal Index 
· Links 






       
Copyright 2019